Kokuyo Camlin

The box every Indian childhood kept

Open any old school bag in this country and you will find the same cast — a Camel geometry box with its scratched lid, a tin of wax crayons, a bottle of poster colour gone half-dry. Kokuyo Camlin, born in Mumbai in 1946 and now part-owned by Japan's Kokuyo, is the company behind most of that. Pens, pencils, crayons, fine-art colours, markers. It sells small things that Indian households buy in large numbers, season after season, exam after exam.

That everyday familiarity is comforting. But a good product and a good *investment* are two different animals, and this note is about the gap between them.

Why it sits in the short-term book, and why now

The honest reason you are reading about Kokuyo Camlin today is price, not glory. The stock has fallen about 32% over the past year, it trades at ₹74.5 against a 52-week high of ₹115, and it is practically sitting on its low of ₹70. Over three years the price has compounded at *minus* 18% a year. This is a wounded stock, not a conquering one, and the short-term thesis here is simply this — a decent brand name with no debt problem has been sold down to a level where mean-reversion over a one-to-six-month window is plausible.

The valuation gives that idea some spine. The current P/E is 33.9. Against its own five-year median of 40.4, that is roughly a 16% discount; against the ten-year median of 53.0, it is a far wider 36% discount. In other words, the market is paying meaningfully less for a rupee of Camlin's earnings today than it has habitually paid across a decade. For a short holding, that re-rating gap is the whole bet.

The business engine — and where it coughs

Now the caution, because the numbers demand it.

Sales tell a bumpy tale. Revenue was ₹544 crore in FY15 and ₹808 crore on a trailing basis today — that works out to a limp 3% compounded over ten years. The five-year figure of 15% looks handsome only because it measures from the Covid pit, when sales collapsed to ₹403 crore in FY21 as schools shut. The last three years grew at 1% a year, and the trailing twelve months at 6%. This is not a company racing ahead; it is one that lost a year to the pandemic and has been clawing its way back to the same ground.

Profits are worse — they lurch. Net profit was ₹44 crore in FY24, then crashed to ₹6 crore in FY25, then recovered to ₹25 crore in FY26. You will see Screener trumpet a TTM profit growth of 6,576%, and you must ignore that number entirely — it is the arithmetic artefact of dividing by a tiny base, not a sign of a business on fire.

The returns confirm the mediocrity. ROCE is 10.2%, ROE just 7.95%, and the three-year average return on equity has hovered near 8%. For a firm that owns one of India's most recognised stationery brands, earning barely more than a fixed deposit on its own capital is a disappointment. Munger would ask the plain question — if the moat is so wide, where is the profit?

What the balance sheet and the register do say

Two things earn genuine credit. First, there has been no dilution — the equity capital has stood unmoved at ₹10 crore from FY15 right through to FY26. Shareholders have not been quietly watered down to fund the journey, which is more than many small-caps can claim. Second, the company has been reducing debt, which pairs well with that clean share count.

The register is steady but not reassuring on the margins. Promoters hold a firm 74.99%, unchanged — the Japanese parent is not going anywhere. But the institutions have walked out: FIIs down to a token 0.10%, DIIs to nil. The smart money, such as it was, has left the room. The dividend yield of 0.40% on a payout under 8% of profits is a token gesture, not a reason to own this.

The verdict

Treat this as what it is — a tactical, beaten-down brand play, not a compounder you tuck away and forget. The appeal is a recognisable franchise, zero dilution, falling debt, and a P/E sitting at a visible discount to its own history while the price loiters near a 52-week low. The danger is equally clear: single-digit ROE, flat decade-long sales, profits that jump around like a cat on a hot tin roof, and institutions already out the door.

For the one-to-six-month horizon of the short-term book, the setup is a *recovery bet on sentiment*, sized small and watched closely, with a strict exit if the re-rating does not arrive. Buy the discount, respect the mediocrity underneath it, and do not confuse childhood nostalgia for a margin of safety.